The Immunology Behind Type 2 Inflammatory Skin Disease

Interleukin-4 and interleukin-13 are considered central drivers of Type 2 inflammation, alongside interleukin-5, which plays a more specific role in eosinophil regulation. These cytokines coordinate various aspects of the allergic immune response, including IgE production and eosinophil recruitment. In atopic dermatitis, interleukin-4 and interleukin-13 signalling contributes directly to skin barrier impairment and inflammatory changes. This shared cytokine biology explains the frequent coexistence of multiple Type 2-driven conditions in the same patient.

Type 2 cytokine signalling has been shown to downregulate key structural proteins involved in maintaining skin barrier integrity, such as filaggrin. This contributes to increased transepidermal water loss and heightened susceptibility to irritants and allergens. The resulting barrier dysfunction and immune activation are thought to reinforce each other, perpetuating the inflammatory cycle characteristic of atopic dermatitis. Addressing this pathway is a key rationale behind targeted biologic therapy in moderate-to-severe disease.

Because Type 2 inflammation is a systemic immune pathway rather than an organ-specific process, patients with one Type 2-driven condition, such as atopic dermatitis, frequently also have others, including asthma or allergic rhinitis. This pattern, sometimes referred to as the atopic march, reflects shared underlying immunology across these conditions. Recognising this overlap can support more coordinated clinical assessment and management. It may also inform decisions around biologic therapies with activity across multiple Type 2-driven indications.